US approves second CAR-T therapy

19th October 2017 Uncategorised 0

Gilead’s Yescarta – recently acquired through its purchase of Kite Pharma – has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.

More: US approves second CAR-T therapy
Source: News